Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FTRE Stock Forecast 2025-2026
$5.22
Current Price
$472.62M
Market Cap
Buy 1
Hold 9
Sell 2
Wall St Analyst Ratings
Distance to FTRE Price Targets
+196.9%
To High Target of $15.50
+14.9%
To Median Target of $6.00
-9.0%
To Low Target of $4.75
FTRE Price Momentum
+5.7%
1 Week Change
-1.1%
1 Month Change
-77.6%
1 Year Change
-72.0%
Year-to-Date Change
-81.6%
From 52W High of $28.41
+31.5%
From 52W Low of $3.97
📊 TOP ANALYST CALLS
Did FTRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fortrea is one of their latest high-conviction picks.
Latest FTRE Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, FTRE has a neutral consensus with a median price target of $6.00 (ranging from $4.75 to $15.50). The overall analyst rating is Buy (6.0/10). Currently trading at $5.22, the median forecast implies a 14.9% upside. This outlook is supported by 1 Buy, 9 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FTRE Analyst Ratings
1
Buy
9
Hold
2
Sell
FTRE Price Target Range
Low
$4.75
Average
$6.00
High
$15.50
Current: $5.22
Latest FTRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FTRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $5.00 |
| May 14, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $8.00 |
| May 13, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $5.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Underweight | Downgrade | $6.00 |
| Apr 9, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $10.00 |
| Mar 4, 2025 | William Blair | Max Smock | Market Perform | Reiterates | $0.00 |
| Mar 4, 2025 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $11.00 |
| Mar 4, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $12.00 |
| Mar 4, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $15.00 |
| Dec 11, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $23.00 |
| Dec 6, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $25.00 |
| Nov 25, 2024 | Baird | Outperform | Maintains | $0.00 | |
| Nov 11, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $30.00 |
| Nov 11, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $25.00 |
| Nov 11, 2024 | TD Cowen | Charles Rhyee | Hold | Maintains | $25.00 |
| Nov 8, 2024 | William Blair | Max Smock | Market Perform | Reiterates | $0.00 |
| Oct 15, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $20.00 |
| Oct 8, 2024 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $20.00 |
| Oct 8, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $23.00 |
| Sep 25, 2024 | Jefferies | David Windley | Hold | Downgrade | $21.00 |
Fortrea Holdings Inc. (FTRE) Competitors
The following stocks are similar to Fortrea based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fortrea Holdings Inc. (FTRE) Financial Data
Fortrea Holdings Inc. has a market capitalization of $472.62M with a P/E ratio of 522.3x. The company generates $2.69B in trailing twelve-month revenue with a -29.4% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of -3.8% and return on equity of -61.6%.
Valuation Metrics
Market Cap
$472.62M
Enterprise Value
$1.63B
P/E Ratio
522.3x
PEG Ratio
4.0x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
-1.6%
Gross Margin
+17.9%
Operating Margin
-3.8%
Net Margin
-29.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.5%
Current Ratio
1.0x
Debt/Equity
149.9x
ROE
-61.6%
ROA
-1.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fortrea Holdings Inc. (FTRE) Business Model
About Fortrea Holdings Inc.
What They Do
Provides global contract research services.
Business Model
The company earns revenue by offering contract research services to pharmaceutical and biotechnology firms, managing their clinical trials from inception to completion. It helps these companies navigate regulatory challenges and ensures compliance with international health standards, which is essential for the successful development and approval of new drugs and therapies.
Additional Information
Fortrea's expertise spans multiple therapeutic areas, including oncology, cardiology, and neurology. Its role is critical in the pharmaceutical supply chain, as it aids in the advancement of medical science and healthcare solutions through efficient trial execution and data management.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15,500
CEO
Mr. Thomas H. Pike
Country
United States
IPO Year
2023
Website
www.fortrea.comFortrea Holdings Inc. (FTRE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jun 26, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Investors in Fortrea Holdings Inc. (NASDAQ: FTRE) have until August 1, 2025, to file a lead plaintiff motion in a class action for securities acquired between July 3, 2023, and February 28, 2025.
Why It Matters
The deadline for filing a lead plaintiff motion in the Fortrea class action signals potential legal risks for investors, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP has filed a class action lawsuit for Fortrea Holdings Inc. (NASDAQ: FTRE) investors, alleging securities fraud from July 3, 2023, to February 28, 2025.
Why It Matters
The class action lawsuit against Fortrea Holdings may signal potential financial instability or fraud, raising concerns about the company's stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts Fortrea Holdings, Inc. (NASDAQ: FTRE) securities purchasers from July 3, 2023, to February 28, 2025, of an August 1, 2025, lead plaintiff deadline.
Why It Matters
The announcement signals potential legal issues for Fortrea Holdings, which can impact stock performance and investor confidence during the class period.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bleichmar Fonti & Auld LLP has filed a lawsuit against Fortrea Holdings Inc. (NASDAQ: FTRE) and its executives for potential federal securities law violations. Investors can seek more info via their website.
Why It Matters
The lawsuit against Fortrea Holdings Inc. could lead to financial penalties and reputational damage, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fortrea Holdings Inc. (NASDAQ: FTRE) shareholders are urged to contact The Gross Law Firm for potential lead plaintiff appointments related to a class action.
Why It Matters
Potential class action notices can indicate legal troubles for Fortrea Holdings, impacting stock performance and investor sentiment. Shareholder actions may influence stock volatility.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Fortrea Holdings Inc. (NASDAQ: FTRE) faces a securities fraud class action lawsuit, with a deadline approaching for investors to join.
Why It Matters
The upcoming deadline for the securities fraud class action against Fortrea Holdings could impact investor sentiment and stock price, highlighting potential legal risks associated with the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FTRE Stock
What is Fortrea Holdings Inc.'s (FTRE) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Fortrea Holdings Inc. (FTRE) has a median price target of $6.00. The highest price target is $15.50 and the lowest is $4.75.
Is FTRE stock a good investment in 2026?
According to current analyst ratings, FTRE has 1 Buy ratings, 9 Hold ratings, and 2 Sell ratings. The stock is currently trading at $5.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FTRE stock?
Wall Street analysts predict FTRE stock could reach $6.00 in the next 12 months. This represents a 14.9% increase from the current price of $5.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fortrea Holdings Inc.'s business model?
The company earns revenue by offering contract research services to pharmaceutical and biotechnology firms, managing their clinical trials from inception to completion. It helps these companies navigate regulatory challenges and ensures compliance with international health standards, which is essential for the successful development and approval of new drugs and therapies.
What is the highest forecasted price for FTRE Fortrea Holdings Inc.?
The highest price target for FTRE is $15.50 from at , which represents a 196.9% increase from the current price of $5.22.
What is the lowest forecasted price for FTRE Fortrea Holdings Inc.?
The lowest price target for FTRE is $4.75 from at , which represents a -9.0% decrease from the current price of $5.22.
What is the overall FTRE consensus from analysts for Fortrea Holdings Inc.?
The overall analyst consensus for FTRE is neutral. Out of 12 Wall Street analysts, 1 rate it as Buy, 9 as Hold, and 2 as Sell, with a median price target of $6.00.
How accurate are FTRE stock price projections?
Stock price projections, including those for Fortrea Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 4:16 PM UTC